Maintenance Therapy in Transplant-Ineligible NDMM

Video

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

OPN-6602 Granted Orphan Drug Designation in R/R Multiple Myeloma

OPN-6602 Granted Orphan Drug Designation in R/R Multiple Myeloma

Tim Cortese
February 16th 2025
Article

Data from a multiple myeloma mouse xenograft model demonstrated promising tumor regression activity from OPN-6602 monotherapy and in combination with standard of care agents.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Cilta-Cel Achieves High MRD Negativity Rates in Lenalidomide-Refractory Multiple Myeloma

Cilta-Cel Achieves High MRD Negativity Rates in Lenalidomide-Refractory Multiple Myeloma

Kristi Rosa
February 15th 2025
Article

Updated CARTITUDE-4 trial data show cilta-cel induces deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma

Roman Fabbricatore
February 11th 2025
Article

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.